Friday 5 from Endocrinology Network - June 4

Endocrinology Network Editorial Staff

The Friday 5 from Endocrinology Network is a list composed by the Endocrinology Network editorial staff aimed at highlighting relevant coverage from endocrinology and endocrinology-related fields.

Every Friday, Endocrinology Network provides a curated list of 5 articles focused or related to a particular topic in endocrinology. This week, the Friday 5 from Endocrinology Network highlights the 5 most popular articles from coverage of the American Academy of Clinical Endocrinology’s 30th Annual Meeting (AACE 2021).

1. More Gradual Dose Titration Could Reduce Hypocortisolism Risk with Osilodrostat in Cushing's Disease

Data from LINC3 and LINC4 provide insight into the impact of dosing titration schedules on risk of hypocortisolism-related adverse events associated with osilodrostat use in patients with Cushing's disease.

2. CGM Use, Visits with Diabetes Educator or Nutritionist Reduce Care Gap Between Pediatric and Adult Diabetes

A retrospective analysis of EHR data suggests use of CGM or visits from a diabetes educator or nutritionist were associated with a decrease in gaps between receiving care at a pediatric endocrinology clinic and an adult clinic.

Interested in more from Endocrinology Network? Subscribe to their free eNewsletters!

3. Study Details Impact of Diabetes on Disease Presentation Among Patients with Thyroid Eye Disease

Analysis of claims data from the Symphony database offers clinicians greater insight into the impact of diabetes, both type 1 and type 2, on thyroid eye disease in US patients.

4. AACE 2021 Study Details SGLT2 Inhibitor Trends in US Diabetes Center

Data from a retrospective review of patients with type 2 diabetes and heart failure at a diabetes center in Maryland details trends in prescribing and discontinuation in a real-world setting over a 5-year period.

5. Analysis Demonstrates MiniMed 670G System Helps Improve A1c and Time in Range in Type 1 Diabetes

A systematic review and meta-analysis of a dozen trials assessing the MiniMed 670G system provides insight into the effects of the hybrid closed-loop system on A1c and time in range among patients with type 1 diabetes.